Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Exclusion Criteria

• •Non-epithelial ovarian carcinomas or ovarian tumors with low malignant potential (i.e., borderline tumors)
• •Another known malignancy that is progressing or requires active treatment (excluding adequately treated basal cell carcinoma or cervical intraepithelial neoplasia/cervical carcinoma in situ or melanoma in situ). Prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.
• •Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.
• •Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
• •Previously treated with a histone deacetylase inhibitor (i.e., vorinostat, belinostat, romidepsin, panobinostat), PD-1/PD-L1-blocking antibody (i.e., atezolizumab, nivolumab, pembrolizumab), or a cytotoxic T-lymphocyte associated protein-4 (CTLA-4) agent
• •Currently enrolled in (or completed) another investigational drug study within 30 days prior to study drug administration
• •A medical condition that precludes adequate study treatment or increases participant risk